Epilepsy Drugs Market PPT: Overview, Dynamics, Trends, Segmentation, Application and Forecast to 2032
                     Global Epilepsy Drugs 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t l ed  "Epi lepsy  Drugs 
Market :  Globa l  Industry  Trends,  Share ,  S ize ,  Growth,  Oppor tun i ty  and 
Forecast  2024-2032 ,"  the  g loba l  ep i lepsy  d rugs  marke t  s ize  reached  US$  2 .3  
B i l l i on  in  2023 .
Factors Af fect ing the Growth of  Epi lepsy Drugs Industry:
Report Increasing Prevalence and Incidence of  Epi lepsy:Ep i lepsy ,  a  neuro log ica l  d iso rde r  charac te r i zed  by  recur ren t  se izu res ,  a f fec ts  
mi l l ions  o f  i nd iv idua ls  wor ldwide .  The  r is ing  p reva lence  and  inc idence  o f  
Highlight and ep i lepsy  a re  s ign i f i can t  d r i ve rs  o f  the  ep i lepsy  d rugs  marke t .  As  awareness  
abou t  ep i lepsy  inc reases  and  d iagnos t i c  capab i l i t ies  imp rove ,  more  cases a re  
Description be ing  iden t i f i ed ,  con t r ibu t ing  to  the  g rowing  pa t ien t  poo l .  
Add i t iona l l y ,  f ac to rs  such  as  ag ing  popu la t ions ,  be t te r  su rv iva l  ra tes  fo r  
cond i t ions  tha t  p red ispose  ind iv idua ls  to  ep i lepsy  (such  as  s t roke  o r  t raumat ic  
b ra in  in ju ry ) ,  and  advancements  in  neona ta l  ca re  lead ing  to  more  p rematu re  
bab ies  su rv iv ing  con t r ibu te  to  the  inc reas ing  bu rden  o f  ep i lepsy .  Th is  
expand ing  pa t ien t  popu la t ion  necess i ta tes  a  con t inuous  supp ly  o f  e f fec t ive  
med ica t ions  to  manage  se izu res  and  imp rove  qua l i t y  o f  l i f e .
Sign i f i can t  Techno logica l  Advancements  in  Drug  Deve lopment :
T he  p h a r m a c eu t i c a l  i nd u s t r y  i s  w i tn e s s i n g  r a p i d  t ec h n o l o g i ca l  ad v a n c e me n t s ,  
pa r t i c u l a r l y  i n  t h e  f i e l d  o f  e p i l e ps y  d r u g  d e v e l op m e n t .  T h es e  a dv a n c em e n ts  i n c l u de  
no v e l  d r u g  de l i v e r y  s y s t e ms ,  i nn o v a t i v e  f o r mu l a t i o ns ,  a n d  s o p h i s t i c a t e d  d r u g  d i sc o v e ry  
t ec h n i q u es  s u c h  as  h i g h - t h r o u gh p u t  s c r e e n i ng  a n d  c om p u ta t i o n a l  mo d e l i n g .  O n e  
Report no t a b l e  a r e a  o f  i n n o v a t i o n  i s  t h e  d e v e l o pm e n t  o f  a n t i e p i l ep t i c  d r u g s  ( A E D s )  w i t h  
i mp r o v ed  e f f i c ac y ,  r ed u c e d  s i d e  e f f e c t s ,  a nd  b e t te r  p h a r m a c ok i n e t i c  p r o f i l e s .  
Highlight and Mo r e o ve r ,  t h e  a d v e n t  o f  p e rs o n a l i ze d  me d i c i n e  a n d  p h a r m a c og e n o mi c s  a l l o w s  f o r  t a i l o r e d  t r e a t me n t  a p p r o a c h e s  b a se d  on  t h e  g e n e t i c  ma k e u p ,  o p t i m i z i n g  t he r a p e u t i c  
ou t c o me s  o f  a n  i n d i v i du a l  a nd  m i n i m i z i n g  a d v e rs e  r ea c t i o n s .  S uc h  t e ch n o l o g i ca l  
Description i n n ov a t i on s  en h a n ce  t h e  e f f i ca c y  a nd  s a f e t y  o f  e p i l e ps y  d ru g s  a n d  o p e n  n ew  a v e nu e s  f o r  t a rg e t i n g  sp e c i f i c  m o l e c u l a r  p a th w a y s  i m p l i c a t e d  i n  s e i z u r e  ge n e r a t i o n  a nd  
p r o p a g a t i o n .
Increas ing  Research  and Deve lopment  Ac t iv i t ies :
T he  e p i l e p sy  d r u g s  ma r k e t  i s  p r o p e l l ed  b y  o ng o i n g  r e s e a rc h  a n d  d e v e l op m e n t  ( R & D )  
e f f o r t s  a i m e d  a t  d i s c o v e r i n g  n ov e l  t he r a p e u t i c  a ge n t s  a n d  i mp r o v i n g  e x i s t i ng  t r ea t m e n t  
mo d a l i t i e s .  P h a rm a c e u t i c a l  c o mp a n i es ,  a ca d e m i c  i n s t i t u t i o n s ,  an d  re s e a r c h  
o r g a n i z a t i o n s  a r e  i n v e s t i n g  he a v i l y  i n  R & D  i n i t i a t i v e s  t o  ad d r e ss  t h e  u n me t  m e d i c a l  
ne e d s  o f  e p i l e ps y  p a t i en t s .
Th is  inc ludes  exp lo r ing  new d rug  ta rge ts ,  e luc ida t ing  the  under ly ing  
pa thophys io logy  o f  ep i lepsy ,  and  conduc t ing  c l i n ica l  t r i a ls  t o  eva lua te  the  
sa fe ty  and  e f f i cacy  o f  po ten t ia l  d rug  cand ida tes .  Fur the rmore ,  co l labora t ions  
be tween  indus t ry  and  academia  fac i l i ta te  the  t rans la t ion  o f  bas ic  research  
f i nd ings  in to  c l i n ica l  app l ica t ions ,  acce le ra t ing  the  d rug  deve lopment  p rocess .  
The  g rowing  unders tand ing  o f  ep i lepsy  as  a  he te rogeneous  d iso rder  w i th  
Report d ive rse  e t io log ies  a l so  d r ives  R&D toward  deve lop ing  ta rge ted  the rap ies  fo r  
spec i f i c  ep i lepsy syndromes and  pa t ien t  popu la t ions ,  f os te r ing  innova t ion  and  
Highlight and advancement  i n  the  ep i lepsy  d rugs  marke t .
Description Request  for  a  PDF sample  o f  th is  repor t :  h t tps : / /www. imarcgroup .com/ep i lepsy-d rugs -marke t / reques tsamp le
Report Description
Global  Epi lepsy Drugs Market  Trends :
The  con t i nuou s  exp ans io n  o f  t r ea t m en t  op t i ons  f o r  e p i l epsy ,  i nc lu d ing  bo t h  t r ad i t i ona l  A EDs  and  n ewer  t he r a p ies ,  f ue l s  
m ar k e t  g r o w t h .  P ha r m aceu t i ca l  co m pa n ies  a r e  i nves t i ng  i n  t he  dev e lopm en t  o f  i nnov a t i ve  d r ugs  w i t h  m echa n ism s  o f  
ac t i on  t a r ge t i n g  no ve l  p a t hwa ys  in vo l ve d  i n  se i z u r e  c on t r o l .  A dd i t i o na l l y ,  non - pha r m aco log i ca l  t r e a t m en t  m oda l i t i e s  su ch  
as  m ed ica l  dev i ce s  and  d ie t a r y  t he r ap ie s  o f f e r  a l t e r na t i ves  f o r  pa t i en t s  w i t h  r e f r ac t o r y  e p i l eps y ,  b r oade n i ng  t h e  
t he r a peu t ic  l an dscap e  an d  d r iv i ng  m ar k e t  ex pans io n .  
M or e ove r ,  e f f o r t s  t o  r a i se  awa r eness  abo u t  e p i l eps y  and  i t s  m anage m en t  hav e  p laye d  a  c r uc ia l  r o le  i n  d r i v i ng  t h e  
ep i l ep sy  d r ugs  m a r ke t .  C am pa i gns  c ond uc t e d  by  hea l t hca r e  o r gan i za t i on s ,  p a t i en t  adv ocacy  g r ou ps ,  and  go ve r n m en t  
agen c ies  a im  t o  edu ca t e  t he  pub l i c ,  he a l t hc a r e  p r o f ess i ona l s ,  and  po l i c ym ak e r s  abou t  ep i l epsy ,  i t s  sym p t om s ,  t r ea t m en t  
op t i on s ,  and  t h e  im po r t anc e  o f  m ed ica t i o n  adhe r ence .  As  a war eness  g r ows ,  m or e  i nd iv idua ls  s eek  m e d ica l  ca r e  f o r  
ep i l ep sy ,  le ad ing  t o  h ighe r  p r es c r i p t i on  r a t es  f o r  an t i e p i l ep t i c  d r u gs  ( A EDs)  and  con t r i bu t i ng  t o  m a r ke t  g r ow t h .
Look i ng  f o rw ar d ,  I M A RC G r oup  ex pec t s  t he  ma rke t  t o  rea ch  US$  4 . 4  B i l l i on  by  2032 ,  ex h i b i t i ng  a  g ro w t h  ra t e  
( CAG R)  o f  7 . 16% dur i n g  202 4 - 20 32 .
V i ew  Repo r t  T O C,  F i g ures  and  T ab l e s :  h t t ps : / / w w w . i mar cgrou p . com / e p i l ep sy - dr ugs- m ark e t
Breakup by Generation Type:
• First  Generat ion Drugs
o Phenytoin
o Carbamazepine
o Oxcarbazepine
o Valproate
o Ethosuximide
Report o Pr imidone
o Phenobarbi ta l
Segmentation
• Second Generat ion Drugs
o Leveti racetam
o Lamotrigine
o Topiramate
o Pregabal in
o Rufi namide
o Zonisamide
• Third Generat ion Drugs
o Lacosamide
o Perampanel
o Esl icarbazepine Acetate
o Ezogabine/Retigabine
Report Breakup by Anti-Epileptics Drugs Type:
Segmentation • Narrow-Spectrum AEDs 
• Broad-Spectrum AEDs
Breakup by Distribution Channel:
• Hospital  Pharmacy
• Pharmacy Stores
• Others
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
Report 
Segmentation
• Abbott Laborator ies
• Alkem Laborator ies Limited
• Bausch Health Companies Inc.
• Eisai Co.  Ltd.
Competitive 
• GSK plc
Landscape • H. Lundbeck A/S
with Key • Jazz Pharmaceuticals plc
• Novart is  AG
Players • Pfi zer Inc.
• Sunovion Pharmaceuticals Inc.  (Sumitomo 
Dainippon Pharma Co. Ltd.)
• UCB S.A.
How has the global epilepsy drugs market performed so 
far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in 
the global epilepsy drugs market?
Key What is the impact of each driver, restraint, and opportunity on the global epilepsy drugs market?
Questions 
What are the key regional markets?
Answered in 
the Report Which countries represent the most attractive epilepsy drugs market?
What is the breakup of the market based on the 
generation type?
Which is the most attractive generation type in the 
epilepsy drugs market?
What is the breakup of the market based on the anti-
epileptics drugs type?
Which is the most attractive anti-epileptics drugs type 
in the epilepsy drugs market?
Key 
What is the breakup of the market based on the 
Questions distribution channel?
Answered in Which is the most attractive distribution channel in the 
epilepsy drugs market?
the Report
What is the competitive structure of the market?
Who are the key players/companies in the global 
epilepsy drugs market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
Table of     2 . 4     M a r k e t  E s t i m a t i o n        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
Contents 4     I n t r o d u c t i o n    4 . 1     O v e r v i e w
    4 . 2     K e y  I n d u s t r y  T r e n d s
5     G l o b a l  E p i l e p s y  D r u g s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  G e n e r a t i o n  T y p e
    6 . 1     F i r s t  G e n e r a t i o n  D r u g s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  K e y  S e g m e n t s
           6 . 1 . 2 . 1  P h e n y t o i n
           6 . 1 . 2 . 2  C a r b a m a z e p i n e
           6 . 1 . 2 . 3  O x c a r b a z e p i n e
           6 . 1 . 2 . 4  V a l p r o a t e
       
           6 . 1 . 2 . 5  E t h o s u x i m i d e
           6 . 1 . 2 . 6  P r i m i d o n e
           6 . 1 . 2 . 7  P h e n o b a r b i t a l
        6 . 1 . 3  M a r k e t  F o r e c a s t
    6 . 2     S e c o n d  G e n e r a t i o n  D r u g s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  K e y  S e g m e n t s
           6 . 2 . 2 . 1  L e v e t i r a c e t a m
           6 . 2 . 2 . 2  L a m o t r i g i n e
           6 . 2 . 2 . 3  T o p i r a m a t e
           6 . 2 . 2 . 4  P r e g a b a l i n
           6 . 2 . 2 . 5  R u f i n a m i d e
Table of            6 . 2 . 2 . 6  Z o n i s a m i d e
        6 . 2 . 3  M a r k e t  F o r e c a s t
    6 . 3     T h i r d  G e n e r a t i o n  D r u g s
Contents         6 . 3 . 1  M a r k e t  T r e n d s        6 . 3 . 2  K e y  S e g m e n t s
           6 . 3 . 2 . 1  L a c o s a m i d e
           6 . 3 . 2 . 2  P e r a m p a n e l
           6 . 3 . 2 . 3  E s l i c a r b a z e p i n e  A c e t a t e
           6 . 3 . 2 . 4  E z o g a b i n e / R e t i g a b i n e
        6 . 3 . 3  M a r k e t  F o r e c a s t
7     M a r k e t  B r e a k u p  b y  A n t i - E p i l e p t i c s  D r u g s  T y p e
    7 . 1     N a r r o w - S p e c t r u m  A E D s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     B r o a d - S p e c t r u m  A E D s
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /e p i l eps y -d rugs -ma rke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]